NGNE Neurogene Inc.companySEC Filings & Insider Trading Activity 2026
Latest Neurogene Inc. (NGNE) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 24, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on April 20, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Neurogene Inc. (NGNE) (SEC CIK 1404644), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • NGN-401 granted FDA Breakthrough Therapy Designation (BTD) — accelerates development, review, and FDA collaboration for Rett syndrome gene therapy
- • BTD is a high-value regulatory milestone: signals FDA sees substantial improvement over existing therapy, typically shortens path to approval
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Neurogene Inc. (NGNE) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 20, 2026 | — | — | — |
8-K | Mar 24, 2026 | — | — | — |
10-K | Mar 24, 2026 | Dec 31, 2025 | — | |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 9, 2025 | Mar 31, 2025 | — | |
10-K | Mar 24, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 18, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | May 10, 2024 | Mar 31, 2024 | — | |
10-K | Mar 18, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 14, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Mar 20, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 14, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Mar 1, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 12, 2021 | Mar 31, 2021 | — | |
10-K | Mar 25, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest NGNE SEC filings in 2026?
Neurogene Inc. (NGNE) has filed a 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on April 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did NGNE file its most recent 10-K annual report?
Neurogene Inc. (NGNE) filed its most recent 10-K annual report on March 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view NGNE 10-Q quarterly reports?
Neurogene Inc. (NGNE)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every NGNE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has NGNE filed recently?
Neurogene Inc. (NGNE)'s most recent 8-K was filed on April 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find NGNE insider trading activity (Form 4)?
SignalX aggregates every NGNE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does NGNE file with the SEC?
Neurogene Inc. (NGNE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NGNE filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Neurogene Inc. (NGNE).
What is NGNE's SEC CIK number?
Neurogene Inc. (NGNE)'s SEC CIK (Central Index Key) number is 1404644. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1404644 to look up all NGNE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find NGNE return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Neurogene Inc. (NGNE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Neurogene Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 52+ filings.